Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Non-Current Assets (2016 - 2026)

Champions Oncology has reported Non-Current Assets over the past 16 years, most recently at $8.3 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $8.3 million for Q1 2026, down 24.41% from a year ago — trailing twelve months through Jan 2026 was $36.6 million (down 20.99% YoY), and the annual figure for FY2025 was $10.0 million, down 20.07%.
  • Non-Current Assets for Q1 2026 was $8.3 million at Champions Oncology, down from $8.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CSBR hit a ceiling of $16.0 million in Q3 2022 and a floor of $8.3 million in Q1 2026.
  • Median Non-Current Assets over the past 5 years was $13.6 million (2024), compared with a mean of $12.9 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 39.57% in 2022 and later dropped 24.41% in 2026.
  • Champions Oncology's Non-Current Assets stood at $15.8 million in 2022, then fell by 9.39% to $14.3 million in 2023, then fell by 21.86% to $11.2 million in 2024, then decreased by 20.85% to $8.8 million in 2025, then decreased by 6.43% to $8.3 million in 2026.
  • The last three reported values for Non-Current Assets were $8.3 million (Q1 2026), $8.8 million (Q4 2025), and $9.5 million (Q3 2025) per Business Quant data.